Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerrit Los

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Cancer Letters|March 27, 2018
Retraction notice to "A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells"Pramod P Mehta, Pei-Pei Kung, Shinji Yamazaki, et al.
Cancer Letters|October 8, 2010
RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cellsPramod P Mehta, Pei-Pei Kung, Shinji Yamazaki, et al.
Molecular Cancer Therapeutics|December 20, 2007
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphomaJames G Christensen, Helen Y Zou, Maria E Arango, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 21, 2010
P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancerGulisa Turashvili, Steven E McKinney, Ozge Goktepe, et al.
Blood Cancer Journal|November 26, 2024
RSK1 dependency in FLT3-ITD acute myeloid leukemiaTim Kong, Angelo B A Laranjeira, Christopher T Letson, et al.
Molecular Cancer Therapeutics|July 16, 2005
Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xLJoshua A Bauer, Douglas K Trask, Bhavna Kumar, et al.
Molecular Pharmacology|May 23, 2003
Diazonamide A and a synthetic structural analog: disruptive effects on mitosis and cellular microtubules and analysis of their interactions with tubulinZobeida Cruz-Monserrate, Hélène C Vervoort, Ruoli Bai, et al.
Journal of the National Cancer Institute|December 25, 2010
Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2Yvette Drew, Evan A Mulligan, Wan-Tse Vong, et al.
Frontiers of Medicine|July 4, 2013
Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell lineDouglas D Fang, Joan Cao, Jitesh P Jani, et al.
Molecular Cancer Therapeutics|April 17, 2008
Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacyCathy Zhang, Karen Lundgren, Zhengming Yan, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Cancer Letters|March 27, 2018
Retraction notice to "A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells"Pramod P Mehta, Pei-Pei Kung, Shinji Yamazaki, et al.
Cancer Letters|October 8, 2010
RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cellsPramod P Mehta, Pei-Pei Kung, Shinji Yamazaki, et al.
Molecular Cancer Therapeutics|December 20, 2007
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphomaJames G Christensen, Helen Y Zou, Maria E Arango, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 21, 2010
P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancerGulisa Turashvili, Steven E McKinney, Ozge Goktepe, et al.
Blood Cancer Journal|November 26, 2024
RSK1 dependency in FLT3-ITD acute myeloid leukemiaTim Kong, Angelo B A Laranjeira, Christopher T Letson, et al.
Molecular Cancer Therapeutics|July 16, 2005
Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xLJoshua A Bauer, Douglas K Trask, Bhavna Kumar, et al.
Molecular Pharmacology|May 23, 2003
Diazonamide A and a synthetic structural analog: disruptive effects on mitosis and cellular microtubules and analysis of their interactions with tubulinZobeida Cruz-Monserrate, Hélène C Vervoort, Ruoli Bai, et al.
Journal of the National Cancer Institute|December 25, 2010
Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2Yvette Drew, Evan A Mulligan, Wan-Tse Vong, et al.
Frontiers of Medicine|July 4, 2013
Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell lineDouglas D Fang, Joan Cao, Jitesh P Jani, et al.
Molecular Cancer Therapeutics|April 17, 2008
Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacyCathy Zhang, Karen Lundgren, Zhengming Yan, et al.
Pageof 3